Source - RNS
RNS Number : 3083K
Avacta Group PLC
09 April 2018
 

 

 

9 April 2018

 

Avacta Group plc

("Avacta", "the Group" or "the Company")

 

Issue of Equity

 

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that application has been made for 10,345 new ordinary shares of 10p each (the "New Ordinary Shares") to be admitted to trading on AIM on 16 April 2018 ("Admission").

 

The New Ordinary Shares have been allotted pursuant to the purchase by Michael Albin, a Non-Executive Director of the Company up to his resignation on 30 March 2018, of New Ordinary Shares in accordance with the terms set out in the Company's announcement of 23 February 2016.

 

Following Admission, the total number of ordinary shares with voting rights in issue will be 68,989,487. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

 

For further information from Avacta Group plc, please contact:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd

Geoff Nash / Giles Rolls - Nominated Adviser

Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking

 

WG Partners

Nigel Birks / Nigel Barnes

David Wilson / Claes Spang

 

Tel:  +44 (0) 207 220 0500

www.finncap.com

 

 

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

 

Yellow Jersey PR (Financial Media and IR)

Sarah Hollins

Tel: +44 (0)7787 502 947

[email protected] 

 

Tel: +44 (0)7764 947137

[email protected]

 

 

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

 

Antibodies dominate markets worth in excess of $100bn despite their shortcomings.  Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

 

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes.  Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.            

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Albin

2.            

Reason for the Notification

a)

Position/status

Non - Executive Director

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

2138009U3EG31OPMGH36

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Ordinary shares of 10p

Identification code

GB00BYYW9G87

b)

Nature of the transaction

 

As set out in the Company's announcement of 23 February 2016, on 22 February 2016 Mr Albin entered into a binding commitment to purchase new Avacta shares amounting to 50% of his contractual non-executive director fee per quarter and the New Ordinary Shares represent his investment for the period of 1 January 2018 to 31 March 2018.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

36.25 pence

10,345

d)

Aggregated information:

·      Aggregated volume

·      Price

 

See above

e)

Date of the transaction

9 April 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEUKVORWNASRAR